VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 1,211 Shares

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 1,211 shares of the firm’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $16.73, for a total transaction of $20,260.03. Following the sale, the insider owned 3,559,243 shares in the company, valued at approximately $59,546,135.39. The trade was a 0.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.

VanEck Biotech ETF Stock Up 1.1%

Shares of BBH traded up $2.26 during trading hours on Thursday, reaching $206.25. 3,431 shares of the stock traded hands, compared to its average volume of 6,008. The company’s 50-day moving average price is $192.26 and its two-hundred day moving average price is $191.76. VanEck Biotech ETF has a 52-week low of $154.75 and a 52-week high of $212.54.

Hedge Funds Weigh In On VanEck Biotech ETF

Several large investors have recently made changes to their positions in BBH. Empowered Funds LLC bought a new position in shares of VanEck Biotech ETF in the fourth quarter worth about $38,000. Flagship Harbor Advisors LLC bought a new stake in VanEck Biotech ETF during the 4th quarter valued at approximately $47,000. Allworth Financial LP raised its stake in VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after purchasing an additional 306 shares during the period. Fifth Third Bancorp purchased a new position in VanEck Biotech ETF in the 1st quarter worth approximately $127,000. Finally, Huntington National Bank purchased a new position in VanEck Biotech ETF in the 4th quarter worth approximately $132,000. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.